

PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM	Books
Search PubMed	▼ for						Go	Clear
<input checked="" type="checkbox"/> Limits		Preview/Index	History	Clipboard	Details			

Entrez  
PubMed

☐ 1: Cell 1991 Sep 20;66(6):1121-31

[Related Articles, Books, Link](#)

[Full Text @ Cell Press](#)

## Membrane organization of the dystrophin-glycoprotein complex.

Ervasti JM, Campbell KP.

Howard Hughes Medical Institute, University of Iowa College of Medicine, Iowa ( 52242.

The stoichiometry, cellular location, glycosylation, and hydrophobic properties of 1 components in the dystrophin-glycoprotein complex were examined. The 156, 59, 43, and 35 kd dystrophin-associated proteins each possess unique antigenic determinants, enrich quantitatively with dystrophin, and were localized to the skeletal muscle sarcolemma. The 156, 50, 43, and 35 kd dystrophin-associated proteins contained Asn-linked oligosaccharides. The 156 kd dystrophin-associated glycoprotein contained terminally sialylated Ser/Thr-linked oligosaccharides. Dystrophin, the 156 kd, and the 59 kd dystrophin-associated proteins were found to be peripheral membrane proteins, while the 50 kd, 43 kd, and 35 kd dystrophin-associated glycoproteins and the 25 kd dystrophin-associated protein were confirmed as integral membrane proteins. These results demonstrate that dystrophin and its 59 kd associated protein are cytoskeletal elements that are tightly linked to a 156 kd extracellular glycoprotein by way of a complex of transmembrane proteins.

PMID: 1913804 [PubMed - indexed for MEDLINE]

Display	Abstract	▼	Sort	▼	Save	Text	Add to Clipboard	Order
---------	----------	---	------	---	------	------	------------------	-------


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Freedom of Information Act](#) | [Disclaimer](#)

spare-sun-solaris2.8 Sep 24 2001 15



PubMed Nucleotide Protein Genome Structure PopSet Taxonomy OMIM Books

Search PubMed ☒ for basement membranes and metastasis Go Clear

☒ Limits Preview/Index History Clipboard Details

Entrez  
PubMed

☐ 1: Cancer Invest 1999;17(1):10-18

Related Articles, Books, Link

## **Influence of antiestrogens on the invasiveness and laminin attachment of breast cancer cells.**

PubMed  
Services

**Rajah TT, Pento JT.**

Department of Pharmacology and Toxicology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.

Related  
Resources

Metastatic spread of breast cancer is responsible for most of the morbidity and mortality associated with this disease. Thus, it is important to identify agents with antimetastatic activity. Because invasiveness and tumor cell attachment are fundamental steps in the metastatic cascade, the major objective of the present study was to evaluate the antimetastatic potential of three antiestrogens, each with different chemical structure and mechanism of action, on breast cancer cell invasiveness and laminin attachment. The antiestrogens examined were tamoxifen, a mixed antagonist/agonist; Analog II, a cyclopropyl antiestrogen with pure antagonist activity and ICI-182,780, a steroidal antiestrogen with pure antagonist activity. Our results indicate that MDA-MB-231 human breast cancer cells are much more invasive and have a higher affinity for laminin than do MCF-7 human breast cancer cells. All the antiestrogens, at a concentration of  $10^{-6}$  M, produced a reduction in MDA-MB-231 cell invasiveness, which was comparable in magnitude to their inhibition of MDA-MB-231 attachment to laminin. Evaluation of MDA-MB-231 cell morphology using scanning electron microscopy revealed the involvement of cellular pseudopods and microvilli in the process of invasion. The results of this study suggest that antiestrogen-induced inhibition of breast cancer cell invasiveness could be due in part to a decrease in the attachment of tumor cells to laminin in the basement membrane.

PMID: 10999044 [PubMed - indexed for MEDLINE]

Display Abstract ☒ Sort ☒ Save Text Add to Clipboard Or

Write to the Help Desk  
NCBI | NLM | NIH  
Department of Health & Human Services  
Freedom of Information Act | Disclaimer



PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	OMIM	Books
Search	PubMed	▼ for					Go	Clear
		✓ Limits	Preview/Index	History	Clipboard	Details		

Entrez  
PubMed

☐ 1: Int J Clin Lab Res 1999;29(1):26-29

[Related Articles, Books, Link](#)

**Research**

## Evaluation of serum laminin as a tumor marker in breast cancer.

**Sidhom G, Imam M.**

Department of Basic Medical Sciences, National Research Center, Cairo, Egypt.

Laminin is a noncollagenous constituent of the extracellular matrix (basement membrane). Increased serum concentrations were recorded in patients with a variety of cancers. The clinical usefulness of serum laminin as a marker for breast cancer was investigated in 60 female patients with malignant breast tumors (30 metastatic, 30 non-metastatic). Subjectively healthy age-matched women (n = 30) served as a control group. Laminin was significantly higher in breast cancer patients than in normal controls. Serum laminin levels were also significantly higher in patients with metastasis than in those without metastasis. A positive correlation was observed between serum laminin and the breast cancer-associated antigen CA 15-3 in the tumor patients. The sensitivity and specificity values of laminin for cancer detection at the optimum decision level [mean + 2 SD (1.4 U/ml)] were 75% and 97% respectively with a 98% positive predictive value, 66% negative predictive value, and 82% diagnostic efficiency. For the detection of metastasis, serum laminin exhibited 77% sensitivity and 100% specificity [best decision level: mean + 2 SD (1.9 U/ml)], with 100% positive predictive value, 81% negative predictive value, and 88% diagnostic efficiency. The latter specificity and positive predictive value were superior to those obtained with serum CA 15-3. These results suggest that serum determination of laminin could be a useful diagnostic tool in breast cancer and a valuable parameter for the prediction of metastasis.

Publication Types:

- Clinical trial

PMID: 10356660 [PubMed - indexed for MEDLINE]

Related  
Resources

Display	Abstract	▼	Sort	▼	Save	Text	Add to Clipboard	Org
---------	----------	---	------	---	------	------	------------------	-----

[Write to the Help Desk](#)